AbbVie, Tizona Collaborating on Development of New CD39-targeted Immunotherapies
News
AbbVie and Tizona Therapeutics are partnering to develop immunotherapies that could reshape the tumor microenvironment and enhance immune responses against cancer cells. The agreement is intended to develop new CD39-targeted ... Read more